223 related articles for article (PubMed ID: 19955909)
1. Proteomic profiling in ovarian cancer.
Kim G; Minig L; Kohn EC
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2(Suppl 2):S2-6. PubMed ID: 19955909
[TBL] [Abstract][Full Text] [Related]
2. Proteomics as a guiding tool for more effective personalized therapy.
Lee JM; Kohn EC
Ann Oncol; 2010 Oct; 21 Suppl 7(Suppl 7):vii205-10. PubMed ID: 20943616
[TBL] [Abstract][Full Text] [Related]
3. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
[TBL] [Abstract][Full Text] [Related]
4. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
5. Proteomics of ovarian cancer: functional insights and clinical applications.
Elzek MA; Rodland KD
Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
[TBL] [Abstract][Full Text] [Related]
6. Predictive modeling in proteomics-based disease detection.
Pham TD
Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():3308-11. PubMed ID: 18002703
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
Ryu J; Thomas SN
Molecules; 2021 May; 26(9):. PubMed ID: 34063568
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer: can proteomics give new insights for therapy and diagnosis?
Toss A; De Matteis E; Rossi E; Casa LD; Iannone A; Federico M; Cortesi L
Int J Mol Sci; 2013 Apr; 14(4):8271-90. PubMed ID: 23591842
[TBL] [Abstract][Full Text] [Related]
9. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.
Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF
J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
Boyce EA; Kohn EC
Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
[TBL] [Abstract][Full Text] [Related]
12. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.
Posadas EM; Davidson B; Kohn EC
Curr Opin Oncol; 2004 Sep; 16(5):478-84. PubMed ID: 15314519
[TBL] [Abstract][Full Text] [Related]
13. Novel proteomic technologies to address gaps in pre-clinical ovarian cancer biomarker discovery efforts.
Jordan HA; Thomas SN
Expert Rev Proteomics; 2023; 20(12):439-450. PubMed ID: 38116719
[TBL] [Abstract][Full Text] [Related]
14. Ovarian Cancer Biomarkers: Moving Forward in Early Detection.
Bonifácio VDB
Adv Exp Med Biol; 2020; 1219():355-363. PubMed ID: 32130708
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer in the proteomics era.
Annunziata CM; Azad N; Dhamoon AS; Whiteley G; Kohn EC
Int J Gynecol Cancer; 2008; 18 Suppl 1():1-6. PubMed ID: 18336391
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of proteomics in ovarian cancer prevention and treatment.
Meani F; Pecorelli S; Liotta L; Petricoin EF
Mol Diagn Ther; 2009; 13(5):297-311. PubMed ID: 19791834
[TBL] [Abstract][Full Text] [Related]
18. Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration.
Galazis N; Olaleye O; Haoula Z; Layfield R; Atiomo W
Fertil Steril; 2012 Dec; 98(6):1590-601.e1. PubMed ID: 22959458
[TBL] [Abstract][Full Text] [Related]
19. Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection.
Barnabas GD; Bahar-Shany K; Sapoznik S; Helpman L; Kadan Y; Beiner M; Weitzner O; Arbib N; Korach J; Perri T; Katz G; Blecher A; Brandt B; Friedman E; Stockheim D; Jakobson-Setton A; Eitan R; Armon S; Brand H; Zadok O; Aviel-Ronen S; Harel M; Geiger T; Levanon K
Mol Cell Proteomics; 2019 May; 18(5):865-875. PubMed ID: 30760538
[TBL] [Abstract][Full Text] [Related]
20. [Early detection of ovarian cancer: tomorrow? A review].
Chene G; Penault-Llorca F; Robin N; Cayre A; Provencher DM; Dauplat J
J Gynecol Obstet Biol Reprod (Paris); 2013 Feb; 42(1):5-11. PubMed ID: 23182787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
